Lynn Tetrault is the Executive Chair and principal executive officer of NeoGenomics, a leading company in the healthcare sector focused on cancer diagnostics and pharmaceuticals. She stepped into this role in March 2022 after serving in various important positions within...

Lynn Tetrault is the Executive Chair and principal executive officer of NeoGenomics, a leading company in the healthcare sector focused on cancer diagnostics and pharmaceuticals. She stepped into this role in March 2022 after serving in various important positions within the company since 2015. Lynn brings over 30 years of experience in the healthcare industry, including significant stints at AstraZeneca, where she was the Executive Vice President for Human Resources and Corporate Affairs. During her time at AstraZeneca, she was pivotal in shaping strategies for talent management and corporate communications. Lynn holds a BA from Princeton University and a JD from the University of Virginia Law School. Besides her role at NeoGenomics, she serves on the boards of Rhythm Pharmaceuticals and Acelyrin. Notably, Lynn's compensation reflects her leadership impact, with a total package reaching $2.5 million in 2022, which included a significant bonus tied to operational performance and growth. Under her guidance, NeoGenomics is committed to enhancing patient care while actively promoting diversity, equity, and inclusion within its workforce.